ALK and non-small cell lung carcinoma: Atezolizumab is another humanized Ig G4-kappa mAb interacting with PD-L1 which [100] in a randomized study, IMpower130 (NCT02367781), of previously untreated NSCLC patients with no EGFR or ALK mutations, demonstrated increased OS and progression-free survival in combination with chemotherapy compared to chemotherapy alone [101].